20n

20n aimed to capitalize on the burgeoning biotech revolution, driven by advancements in DNA sequencing, synthesis, and computational prediction. While sequencing and synthesis technologies have become increasingly accessible, 20n focused on developing computational systems to predict optimal DNA designs for innovative applications in industrial biotech and healthcare. The company adopted a big data approach, leveraging machine learning, distributed systems, AI planning, program synthesis, data mining, and natural language processing to transform biological data into actionable information. With backing from DARPA, 20n assembled a multidisciplinary team of computer scientists and bioengineers to explore biology through a novel lens. Their target customers were industrial biotech firms pioneering the shift towards sustainable biological manufacturing processes for fuels, materials, therapeutics, and flavors, enabling them to access previously unattainable markets.